Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Foley

Showing results (111-120 of 185) with videos related to

Pageof 19
Sort By:
International Journal of Dermatology|April 14, 2015
A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosisEggert Stockfleth, Ketty Peris, Carlos Guillen, et al.
American Journal of Clinical Dermatology|September 10, 2020
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 StudyKristian Reich, April W Armstrong, Peter Foley, et al.
JAMA Dermatology|May 26, 2018
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical TrialsPeter Foley, Kenneth Gordon, Christopher E M Griffiths, et al.
Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trialKristian Reich, April W Armstrong, Peter Foley, et al.
The Journal of Dermatological Treatment|May 23, 2022
Preliminary efficacy and safety analysis: 12-month results in 83 patients using a novel approach of widefield radiation therapy for extensive skin field cancerization with or without keratinocyte cancersAndrew E Potter, Christopher Baker, Stephen Shumack, et al.
Dermatology and Therapy|August 23, 2024
Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation AnalysisApril W Armstrong, Peter Foley, Yan Liu, et al.
The Australasian Journal of Dermatology|June 3, 2015
Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in AustraliaJo-Ann See, Stephen Shumack, Dedee F Murrell, et al.
The Australasian Journal of Dermatology|August 11, 2020
Management of chronic hand and foot eczema. An Australia/New Zealand Clinical narrativeMarius Rademaker, Katherine Armour, Christopher Baker, et al.
International Journal of Dermatology|July 29, 2024
A global perspective on the treatment and maintenance of mature skin using gentle cleansers and moisturizersJoachim W Fluhr, Andrew F Alexis, Anneke Andriessen, et al.
Journal of the American Academy of Dermatology|December 28, 2006
Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005Lasse R Braathen, Rolf-Markus Szeimies, Nicole Basset-Seguin, et al.
Pageof 19

Showing results (111-120 of 185) with videos related to

Sort By:
Pageof 19
International Journal of Dermatology|April 14, 2015
A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosisEggert Stockfleth, Ketty Peris, Carlos Guillen, et al.
American Journal of Clinical Dermatology|September 10, 2020
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 StudyKristian Reich, April W Armstrong, Peter Foley, et al.
JAMA Dermatology|May 26, 2018
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical TrialsPeter Foley, Kenneth Gordon, Christopher E M Griffiths, et al.
Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trialKristian Reich, April W Armstrong, Peter Foley, et al.
The Journal of Dermatological Treatment|May 23, 2022
Preliminary efficacy and safety analysis: 12-month results in 83 patients using a novel approach of widefield radiation therapy for extensive skin field cancerization with or without keratinocyte cancersAndrew E Potter, Christopher Baker, Stephen Shumack, et al.
Dermatology and Therapy|August 23, 2024
Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation AnalysisApril W Armstrong, Peter Foley, Yan Liu, et al.
The Australasian Journal of Dermatology|June 3, 2015
Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in AustraliaJo-Ann See, Stephen Shumack, Dedee F Murrell, et al.
The Australasian Journal of Dermatology|August 11, 2020
Management of chronic hand and foot eczema. An Australia/New Zealand Clinical narrativeMarius Rademaker, Katherine Armour, Christopher Baker, et al.
International Journal of Dermatology|July 29, 2024
A global perspective on the treatment and maintenance of mature skin using gentle cleansers and moisturizersJoachim W Fluhr, Andrew F Alexis, Anneke Andriessen, et al.
Journal of the American Academy of Dermatology|December 28, 2006
Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005Lasse R Braathen, Rolf-Markus Szeimies, Nicole Basset-Seguin, et al.
Pageof 19